Design and Analysis of Cross-Over Trials
Latest Publications


TOTAL DOCUMENTS

27
(FIVE YEARS 0)

H-INDEX

1
(FIVE YEARS 0)

Published By Chapman And Hall/CRC

9780429126000






population of potential patients, but be such that they produce different effects when a patient is switched from formulation T to formulation R or vice-versa. In other words there is a significant subject-by-formulation interaction. To show that this is not the case T and R have to be shown to be IBE, i.e., individually bioequivalent. The measure of IBE that has been suggested by the regulators is an aggregate measure involving the means and variances of T and R and the subject-by-formulation inter-action. We will describe this measure in Section 7.4. In simple terms PBE can be considered as a measure that permits patients who have not yet been treated with T or R to be safely prescribed either. IBE, on the other hand, is a measure which permits a patient who is cur-rently being treated with R to be safely switched to T (FDA Guid-ance, 1997, 1999a,b, 2000, 2001). It is worth noting that if T is IBE to R it does not imply that R is IBE to T. The same can be said for PBE. An important practical implication of testing for IBE is that the 2×2 cross-over trial is no longer adequate. As will be seen, the volunteers in the study will have to receive at least one repeat dose of R or T. In other words, three-or four-period designs with sequences such as [RTR,TRT] and [RTRT,TRTR], respectively, must be used. The measures of ABE, PBE and IBE that will be described in Sec-tions 7.2, 7.5 and 7.4 are those suggested by the regulators. Dragalin and Fedorov (1999) and Dragalin et al. (2002) have pointed out some drawbacks of these measures and suggested alternatives which have more attractive properties. We will consider these alternatives in Section 7.7. All the analyzes considered in Sections 7.2 to 7.4 are based on sum-mary measures (AUC and Cmax) obtained from the concentration-time profiles. If testing for bioequivalence is all that is of interest, then these measures are adequate and have been extensively used in practice. How-ever, there is often a need to obtain an understanding of the absorb-tion and elimination processes to which the drug is exposed once it has entered the body, e.g., when bioequivalence is not demonstrated. This can be done by fitting compartmental models to the drug con-centrations obtained from each volunteer. These models not only pro-vide insight into the mechanisms of action of the drugs, but can also be used to calculate the AUC and Cmax values. In Section 7.8 we de-scribe how such models can be fitted using the methods proposed by Lindsey et al. (2000a). The history of bioequivalence testing dates back to the late 1960s and early 1970s. Two excellent review articles written by Patterson (2001a, 2001b) give a more detailed description of the history, as well as a more extensive discussion of the points raised in this section. The regulatory


the ‘Area Under the Curve’ or AUC. The AUC is taken as a measure of exposure of the drug to the subject. The peak or maximum concen-tration is referred to as Cmax and is an important safety measure. For regulatory approval of bioequivalence it is necessary to show from the trial results that the mean values of AUC and Cmax for T and R are not significantly different. The AUC is calculated by adding up the ar-eas of the regions identified by the vertical lines under the plot in Figure 7.1 using an arithmetic technique such as the trapezoidal rule (see, for example, Welling, 1986, 145–149, Rowland and Tozer, 1995, 469–471). Experience (e.g., FDA Guidance, 1992, 1997, 1999b, 2001) has dictated that AUC and Cmax need to be transformed to the natural logarithmic scale prior to analysis if the usual assumptions of normally distributed errors are to be made. Each of AUC and Cmax is analyzed separately and there is no adjustment to significance levels to allow for multiple testing (Hauck et al., 1995). We will refer to the derived variates as log(AUC) and log(Cmax), respectively. In bioequivalence trials there should be a wash-out period of at least five half-lives of the drugs between the active treatment periods. If this is the case, and there are no detectable pre-dose drug concentrations, there is no need to assume that carry-over effects are present and so it is not necessary to test for a differential carry-over effect (FDA Guidance, 2001). The model that is fitted to the data will be the one used in Section 5.3 of Chapter 5, which contains terms for subjects, periods and treatments. Following common practice we will also fit a sequence or group effect and consider subjects as a random effect nested within sequence. An example of fitting this model will be given in the next section. In the following sections we will consider three forms of bioequivalence: average (ABE), population (PBE) and individual (IBE). To simplify the following discussion we will refer only to log(AUC); the discussion for log(Cmax) is identical. To show that T and R are average bioequivalent it is only necessary to show that the mean log(AUC) for T is not significantly different from the mean log(AUC) for R. In other words we need to show that, ‘on average’, in the population of intended patients, the two drugs are bioequivalent. This measure does not take into account the variability of T and R. It is possible for one drug to be much more variable than the other, yet be similar in terms of mean log(AUC). It was for this reason that PBE was introduced. As we will see in Section 7.5, the measure of PBE that has been recommended by the regulators is a mixture of the mean and variance of the log(AUC) values (FDA Guidance, 1997, 1999a,b, 2000, 2001). Of course, two drugs could be similar in mean and variance over the


5 Population bioequivalence As noted in Section 7.1, population bioequivalence (PBE) is concerned with assessing whether a patient who has not yet been treated with R or T can be prescribed either formulation. It can be assessed using the following aggregate metric (FDA Guidance, 1997). (µ (7.8) max(0.04,σ ) where σ and σ . As long as an appropriate mixed model is fitted to the data, this metric can be calculated using data from a 2×2 design or from a replicate design. Using data from Sections 7.2 and 7.4, we will illustrate the calculation of the metric in each of the two designs. 7.5.1 PBE using a 2× 2 design As in the previous section we will test for equivalence using a linearized version of the metric and test the null hypotheses: H : ν = δ +σ − (1 + c when σ > 0.04 or H : ν = δ +σ −σ (0.04) ≥ 0, (7.10) when σ > 0.04, where σ and σ are the between-subject variances of T and R, re-spectively. Let ω denote the between-subject covariance of T and R and σ denote the variance of δˆ = µˆ . The REML estimates of σ , o  btained from using the SAS code in Appendix B, are asymptoti-cally normally distributed with expecta  tion vector   σ   l lT×ω σ and variance-covariance matrix l lT×ω l lω Then νˆ = δˆ + σˆ − (1 + c )σˆ (7.11) is an estimate for the reference-scaled PBE metric in accordance with FDA Guidance (2001) when σˆ > 0.04 and using a REML UN model. This estimate is asymptotically normally distributed and unbiased (Pat-terson, 2003; Patterson and Jones, 2002b) with E[νˆ ] = δ +σ


Sign in / Sign up

Export Citation Format

Share Document